Vanda Pharma Q2 2024 GAAP EPS $(0.08) Beats $(0.21) Estimate, Sales $50.474M Beat $47.860M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals (NASDAQ:VNDA) reported Q2 2024 GAAP EPS of $(0.08), beating the estimate of $(0.21) by 61.9%. Sales were $50.474M, surpassing the $47.860M estimate and showing a 9.59% increase from the same period last year.
July 31, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vanda Pharmaceuticals reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.08) beating the $(0.21) estimate and sales of $50.474M surpassing the $47.860M estimate. Sales increased by 9.59% YoY.
The better-than-expected earnings and revenue figures are likely to positively impact VNDA's stock price in the short term. Beating both EPS and sales estimates, along with a significant YoY sales increase, indicates strong performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100